FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin‐Containing Chemotherapy

The U.S. Food and Drug Administration (FDA) granted accelerated approval to atezolizumab and pembrolizumab in April and May 2017, respectively, for the treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin‐containing chemotherapy. These app...

全面介紹

Na minha lista:
書目詳細資料
發表在:Oncologist
Main Authors: Suzman, Daniel L., Agrawal, Sundeep, Ning, Yang‐min, Maher, V. Ellen, Fernandes, Laura L., Karuri, Stella, Tang, Shenghui, Sridhara, Rajeshwari, Schroeder, Jason, Goldberg, Kirsten B., Ibrahim, Amna, McKee, Amy E., Pazdur, Richard, Beaver, Julia A.
格式: Artigo
語言:Inglês
出版: John Wiley & Sons, Inc. 2018
主題:
Regulatory Issues: FDA
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC6459239/
https://ncbi.nlm.nih.gov/pubmed/30541754
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0084
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍